
CTOR
Healthcare · Drug Manufacturers - Specialty & Generic · $60.7M market cap
$0.5738+0.05 (+9.9%)Nov 13, 4:00 PM EST
Next report
Time not confirmed
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · +63.2% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Dec 22, 2026 · upcoming | Time not confirmed | — | — | — |
| Aug 14, 2026 | After the close | -0.07 | -0.08 | -14.3% |
| May 15, 2026 | After the close | -0.01 | -0.27 | -2600.0% |
| Feb 13, 2026 | Time not confirmed | -0.02 | -0.06 | -200.0% |
| Dec 23, 2025 | After the close | -0.06 | -0.06 | 0.0% |
| Aug 12, 2025 | After the close | -0.15 | -0.08 | +46.7% |
| May 14, 2025 | After the close | -0.09 | -0.11 | -22.2% |
| Feb 17, 2025 | Time not confirmed | -0.06 | -0.09 | -55.2% |
| Dec 30, 2024 | Time not confirmed | -0.08 | -0.31 | -282.4% |
| Aug 28, 2024 | Time not confirmed | — | 0.04 | — |
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron…